Tyligand Bioscience Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • IPO Registration

  • Employees
  • 64

Employees

  • Latest Deal Type
  • IPO
  • (Announced)

  • Investors
  • 14

Tyligand Bioscience General Information

Description

Developer and manufacturer of oral oncology drugs and antibody-drug conjugate platforms designed for KRAS-mutated and other solid tumors. The company provides clinical-stage drug candidates and a differentiated therapeutic pipeline, enabling cancer patients and healthcare providers with novel treatment mechanisms, improved survival outcomes, and solutions for unmet clinical needs.

Contact Information

Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Corporate Office
  • West Building, Building 1
  • No. 3728 Jinke Road, Pudong New Area
  • Shanghai, 201203
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • West Building, Building 1
  • No. 3728 Jinke Road, Pudong New Area
  • Shanghai, 201203
  • China
+86 021

Tyligand Bioscience Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tyligand Bioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. IPO 29-Jan-2026 Announced Generating Revenue
7. Later Stage VC (Series B) 26-Jan-2026 Completed Generating Revenue
6. Secondary Transaction - Private 08-Sep-2025 Completed Generating Revenue
5. Secondary Transaction - Private 08-Jan-2025 Completed Generating Revenue
4. Later Stage VC (Series A2) 17-Apr-2024 Completed Generating Revenue
3. Later Stage VC (Series A1) 28-Jun-2023 Completed Clinical Trials - General
2. Early Stage VC (Series A) 19-Apr-2021 $20M $28M Completed Clinical Trials - General
1. Early Stage VC 10-Sep-2018 $8.03M $8.03M Completed Startup
To view Tyligand Bioscience’s complete valuation and funding history, request access »

Tyligand Bioscience Patents

Tyligand Bioscience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026138732-A1 Antibody-drug conjugate and use thereof Pending 24-Dec-2024
WO-2026051996-A1 Dual-payload antibody-drug conjugate and use thereof Pending 04-Sep-2024
WO-2025214431-A1 Hyaluronic acid cross-linked conjugate loaded with capsaicin Pending 11-Apr-2024
AU-2025208223-A1 Antibody-drug conjugate and use thereof Pending 08-Jan-2024
WO-2025148868-A1 Antibody-drug conjugate and use thereof Inactive 08-Jan-2024 A61K47/6803
To view Tyligand Bioscience’s complete patent history, request access »

Tyligand Bioscience Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tyligand Bioscience Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Tencent Holdings Corporation Minority
LAV (Lilly Asia Fund) Corporate Venture Capital Minority
Calor Capital Venture Capital Minority
Hangzhou Tailong Venture Capital Partnership Growth/Expansion Minority
Ming Bioventures Venture Capital Minority
You’re viewing 5 of 14 investors. Get the full list »

Tyligand Bioscience FAQs

  • When was Tyligand Bioscience founded?

    Tyligand Bioscience was founded in 2018.

  • Where is Tyligand Bioscience headquartered?

    Tyligand Bioscience is headquartered in Shanghai, China.

  • What is the size of Tyligand Bioscience?

    Tyligand Bioscience has 64 total employees.

  • What industry is Tyligand Bioscience in?

    Tyligand Bioscience’s primary industry is Drug Discovery.

  • Is Tyligand Bioscience a private or public company?

    Tyligand Bioscience is a Private company.

  • What is Tyligand Bioscience’s current revenue?

    The current revenue for Tyligand Bioscience is .

  • How much funding has Tyligand Bioscience raised over time?

    Tyligand Bioscience has raised $111M.

  • Who are Tyligand Bioscience’s investors?

    Tencent Holdings, LAV (Lilly Asia Fund), Calor Capital, Hangzhou Tailong Venture Capital Partnership, and Ming Bioventures are 5 of 14 investors who have invested in Tyligand Bioscience.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process